Bioshares latest addition included an update on Opthea. Here are...

Bioshares latest addition included an update on Opthea.

Here are a few edited highlights. Opthea is building a compelling case for its ophthalmology drug candidate,OPT-302. Having delivered positive results in the first indication of wet AMD in a PhaseIb/IIa trial last year, it has now produced early positive data from its Phase Ib/IIa study indiabetic macular edema. It is also strengthening the scientific rationale that underpinsits technology, which will support a future commercial transaction of OPT-302.

In relation to the DME trial.  In the five patients with bilateral disease, Opthea plus Eylea achieved a mean 10 lettergain in vision compared to only a 2.6 letter improvement in patients receivingEylea in the second eye. The combinationtreatment achieved a central subfield thickness reduction of 80uM compared to just a 6uM reduction in theEylea only treatment alone. 

It was also explained why the mechanism of action of OPT-302  may have efficacy in DME

The company expects to receive a $12 million tax rebate forlast financial year.

Although data for its two trials is between 12 - 18 months away,investors with patience may be very well rewarded with this stock.The company's core asset OPT-302 has the potential to deliversubstantial value to the company if positive trial data continues to flow.